A recent meta-analysis showed that recombinant endostatin, Endostar (rh‐endostatin), approved for clinical use in China for almost 20 years, improved the prognosis of non‐small cell lung cancer patients with bone metastases when used in combination with other chemotherapeutic agents (221–223). This evidence concerns the gene COL18A1 and lung cancer.